ArticleFrontiers in endocrinology2024
Predictors of lateral lymph node metastasis and skip metastasis in patients with papillary thyroid microcarcinoma.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interpretable machine learning distinguishes skip from continuous metastasis in N1b papillary thyroid carcinoma.Scientific reports · 2026Article
- Radiomics-based prediction model for lymph node metastasis in thyroid microcarcinoma.BMC surgery · 2026Article
- Risk factors for lateral and skip lymph node metastasis in adolescents and young adults with papillary thyroid carcinoma.Gland surgery · 2026Article
- Predictive significance of anterior and posterior minimal extrathyroidal extension for central lymph node metastasis in cN0 papillary thyroid carcinoma.Clinical & experimental metastasis · 2026Article
- Prediction of lymph node metastasis in cN0 papillary thyroid carcinoma using a random forest-based radiomics model integrating contrast-enhanced ultrasound and clinical data.Frontiers in oncology · 2026Article
- Skip metastases in papillary thyroid carcinoma: evidence from a multicenter European retrospective study.Frontiers in endocrinology · 2026Observational
- Papillary thyroid carcinoma and primary aldosteronism: A new syndrome or a mere association?World journal of clinical cases · 2025Article
- Contralateral metastatic papillary thyroid carcinoma and complicated by primary hyperaldosteronism: A case report.World journal of clinical cases · 2025Article
- Predictive Factors of Lymph Node Metastasis in Papillary Thyroid Microcarcinoma (PTMC).Medicina (Kaunas, Lithuania) · 2025Article
- Predicting the Unexpected: Clinicopathological Insights into Skip Metastasis in Papillary Thyroid Carcinoma.Journal of clinical medicine · 2025Article
- Article
- Risk factors for predicting lateral lymph node metastasis of papillary thyroid carcinoma based on LASSO-logistic regression.Frontiers in endocrinology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid microcarcinoma (PTMC) is characterized by its favorable prognosis and potential for active surveillance (AS) as a management option. However, the presence of cervical lymph node (LN) metastasis, especially lateral LN metastasis, significantly impacts management and prognosis. Previous studies have focused on post-surgery risk factors for cervical LN metastasis. This study aims to identify predictors of lateral LN metastasis by analyzing pre-operative ultrasonographic findings alongside clinicopathological factors. Methods: A retrospective review of medical records was conducted for patients with PTMC who underwent surgery at Chonnam National University Hwasun Hospital between 2004 and 2013. This is a case-control study that compares patients with lateral LN metastasis (N1b) to age- and sex-matched patients without LN metastasis (N0). Subgroup analysis was performed to evaluate risk factors of skip metastasis. Results: The study included 90 patients with PTMC with lateral LN metastasis (N1b) and 268 age- and sex-matched patients without LN metastasis (N0). The mean age was 49.3 years, and female patients were dominant in both groups. Structural recurrences of 4.4% (4/90) were observed only in the N1b group. The N1b group exhibited a higher frequency of upper lobe tumor location compared to the N0 group (38.9% vs. 16.0%, Conclusion: Detailed ultrasound examinations, evaluating tumor location, number, orientation, and the presence of ETE, are crucial in accurately predicting lateral LN metastasis especially when primary tumor was in the upper lobe to avoid missing skip metastasis. These evaluations can help guide the decision between AS and immediate surgery in patients with PTMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.